Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting rapid TKI ‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3 / ITD acute myeloid leukemia

Molecular Oncology(2024)10.1002/1878-0261.13749Source: DataRank Database

Targeting rapid TKI ‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3 / ITD acute myeloid leukemia is a research paper published in Molecular Oncology (2024). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

cellosaurus nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.90)OA: goldTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Li Li ORCID,J. Kyle Bruner,Melody Chou,Bao Nguyen ORCID,Jaesung Seo

Live enrichment

PubMed:39395205 PMC:PMC12077278 OpenAlex:https://openalex.org/W4403351501

Common Fund

Grant: P30 CA006973

Giant Food Pediatric Cancer Fund

FWCI

0.90

Citation Percentile

0.7%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.13749

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.13749

publisherhttps://febs.onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13749

journalhttps://doi.org/10.1002/1878-0261.13749

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39395205

Fields of Study

Phagocytosis and Immune RegulationProtein Degradation and InhibitorsChronic Myeloid Leukemia Treatmentsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteReceptor Protein-Tyrosine KinasesProto-Oncogene ProteinsHumansAxl Receptor Tyrosine KinaseProtein Kinase InhibitorsAnimalsUp-RegulationCell Line, TumorExtracellular Signal-Regulated MAP KinasesMiceTandem Repeat SequencesXenograft Model Antitumor AssaysMAP Kinase Signaling System

MeSH Terms

Axl Receptor Tyrosine KinaseAnimalsHumansProto-Oncogene ProteinsLeukemia, Myeloid, AcuteUp-RegulationTandem Repeat SequencesReceptor Protein-Tyrosine KinasesMAP Kinase Signaling SystemXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsExtracellular Signal-Regulated MAP KinasesMicefms-Like Tyrosine Kinase 3

Keywords

MAPK/ERK pathwayDownregulation and upregulationMyeloid leukemiaCancer researchReceptor tyrosine kinaseTyrosine kinaseFms-Like Tyrosine Kinase 3AXL receptor tyrosine kinaseKinaseSignal transductionPharmacologyMedicineBiologyCell biologyJAK-STAT signaling pathwayBiochemistryMutationAdaptive responseTargeted TherapyCancer ResistanceRtk SignalingFlt3/itd Aml

Sustainable Development Goals

SDG 0: No poverty

Targeting rapid TKI ‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3 / ITD acute myeloid leukemia

FAIR Checklist

Authors (10)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)